The shares sold off, however the CC was pretty positive. Most questions were on the likelihood and parameters of a Phase III trial in HCC. Suggestion was that if they go ahead first dosing is likely to be in Q1/13. Final read-out of the lung cancer Phase III trial is likely to be in the first half of 2013 with an interim report in the second half of 2012. Arqule has now secured its capital needs until the end of 2014.
It was a good CC: - It appears that the management understands the complexity of oncology drug development process. The past shortcuts were fatal for many biotech companies. The management goal is to get a regulatory approval rather than advance the science. - There will be very few if any new data in the to be published ASCO HCC PH II abstract. The ASCO presented data will not be final results with follow-on presentations at later dates. This tells me that ARQL is not in a great hurry to start a HCC PhIII trial. Nothing is wrong with it. - Very little was said about the ARQL pipeline development progress outside of ARQ 197.
On a negative side, I wish, the CEO had a better English.
What do you mean by "There will be very few if any new data in the to be published ASCO HCC PH II abstract"? It clearly stating in latest PR that there will ne new data. "We look forward to presenting additional data from this trial at the Annual Meeting of the American Society of Clinical Oncology in June, including secondary endpoint, sub-group and biomarker analyses"